A Meta-analysis of the evaluation of the effectiveness of available treatments for Alzheimer’s Disease

Abstract

The importance of memantine and cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease (AD) is highlighted by this meta-analysis. Even though these pharmaceutical therapies have limited advantages, they are vital in helping patients live better lives and lighten the load on caregivers. These conclusions are supported by data from our study conducted at the Central University Hospital (CHU) in Tlemcen, which shows significant improvements in cognitive function in individuals using memantine and donepezil with little side effects. Notwithstanding these encouraging results, the data also show that additional extensive, rigorous trials are required to validate the slight variations noted between the treatment and placebo groups. For these treatments to be shown safe and effective on a larger scale, such studies are necessary. This argument has also emphasised the necessity of ongoing innovation in the treatment of AD. A greater comprehension of the physiopathology of the disease and the development of novel therapies are necessary due to the rising global burden of Alzheimer's disease. Given the complexity of Alzheimer's disease, comprehensive approaches and alternative therapeutics beyond symptomatic treatment should be investigated.